| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BeiGene Ltd. | Tislelizumab - (Rationale-301) | Hepatocellular carcinoma (HCC) | Phase 3 | Intravenous | Oncology | |
| BeiGene Ltd. | Pamiparib (BGB-290) | Maintenance Therapy Ovarian Cancer | Phase 3 | Oral | Oncology | |
| BeiGene Ltd. | Tislelizumab - (RATIONALE 303) | Non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeiGene Ltd. | Tislelizumab | Squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeiGene Ltd. | Tislelizumab - (RATIONALE 309) | Nasopharyngeal cancer (RM-NPC) | Phase 3 | Intravenous | Oncology | |
| BeiGene Ltd. | Tislelizumab and chemotherapy - (RATIONALE 304) | Non-squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeiGene Ltd. | Tislelizumab and chemoradiotherapy | Esophageal squamous cell carcinoma (ESCC) | Phase 3 | Trial Completed | Intravenous | Oncology |
| Belite Bio Inc | Tinlarebant - (DRAGON II) | Stargardt Disease | Phase 2/3 | Enrollment Initiation | Oral | #N/A |